The main downstream effector of ACK1 is AR, and both breast and prostate cancers are hormone-regulated cancers, indicating the potential of ER as another hormone receptor that interacts with ACK1, possibly making breast cancer cells more sensitive to radiotherapy by inhibiting ACK1-ER signaling. This evidence concerns the gene TNK2 and breast carcinoma.